---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001049"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:41:47.993643+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign

## Summary
- All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.
- Lindsay Androski named President and CEO, replacing interim CEO McElhaugh; she also serves as board chair.
- Androski receives $515k salary, 45% target bonus, and ~$750k option grant; three new directors are from Roivant.
- Company will pause investor meetings to review strategic options for hepatitis B pipeline and development plans.

## SEC filing metadata
- accession: 0001171843-25-001049
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/f8k_022525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001049
- JSON: https://secwatch.observer/filing/0001171843-25-001049.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001049.txt

## Key facts
- Executive change
  Daniel Burgess resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: Daniel Burgess
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Lindsay Androski was appointed as Chief Executive Officer at Arbutus Biopharma Corp.
  - Role: Chief Executive Officer
  source text: Ms. Androski, as Chief Executive Officer of the Company, will not receive compensation for her service as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  James Meyers resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: James Meyers
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Richard C. Henriques resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: Richard C. Henriques
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Frank Torti resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: Frank Torti, M.D., chairperson of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Melissa V. Rewolinski resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: Melissa V. Rewolinski, Ph.D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Keith Manchester resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: Keith Manchester, M.D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Lindsay Androski was appointed as Chairperson of the Board at Arbutus Biopharma Corp.
  - Action: appointed
  - Role: Chairperson of the Board
  source text: appointed Ms. Androski as chairperson of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
- Executive change
  Michael J. McElhaugh resigned as Director at Arbutus Biopharma Corp.
  - Action: resigned
  - Role: Director
  source text: Michael J. McElhaugh
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.